Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2013

01-06-2013 | Original Article

Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience

Authors: Abdullah Ozkok, Timur Selcuk Akpinar, Fatih Tufan, Nilufer Alpay Kanitez, Mukremin Uysal, Metban Guzel, Yasar Caliskan, Sabahat Alisir, Halil Yazici, Tevfik Ecder

Published in: Clinical and Experimental Nephrology | Issue 3/2013

Login to get access

Abstract

Background

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease. The course and progression of the disease is highly variable. In this study, we aimed to investigate the impact of clinical characteristics and basic biochemical parameters on progression of chronic kidney disease (CKD) in ADPKD patients.

Materials and methods

A total of 323 consecutive patients with ADPKD were enrolled into the study and followed with a mean duration of 100 ± 38 months. Patients were grouped as rapid progressors (RP) and slow progressors (SP) according to median rates of decline in glomerular filtration rate (ΔGFR) per year, namely 1 ml/min/year.

Results

History of macroscopic hematuria, urinary stone and smoking were more common in male patients; hepatic and other organ cysts were more common in female patients. ∆GFR/year was similar between males and females [0.95 (0–3.02) vs. 1.11 (0.10–2.74) ml/min/year, p = 0.21]. History of smoking and pack-year of cigarettes smoked were significantly higher in the RP compared to the SP group (36 vs. 18 %, p = 0.01 and 5.24 ± 1.20 vs. 3 ± 1.32 pack-year, p = 0.02, respectively). Baseline 24 h-proteinuria was found to be significantly correlated with the percent decline of GFR (∆%GFR) per year (r = 0.303, 0.001). In Cox regression analysis for predicting the progression of CKD, age, hypertension, urinary stone and proteinuria were retained as the significant independent factors predicting progression of CKD in the model.

Conclusion

Baseline proteinuria was significantly correlated with ∆%GFR per year. Hypertension and proteinuria were found to be the major treatable risk factors for the progression of CKD in ADPKD patients.
Literature
1.
go back to reference Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW, editors. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007. Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW, editors. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007.
2.
go back to reference Sessa A, Righetti M, Battini G. Autosomal recessive and dominant polycystic kidney diseases. Minerva Urol Nefrol. 2004;56:329–38.PubMed Sessa A, Righetti M, Battini G. Autosomal recessive and dominant polycystic kidney diseases. Minerva Urol Nefrol. 2004;56:329–38.PubMed
3.
go back to reference Pei Y. Molecular genetics of autosomal dominant polycystic kidney disease. Clin Invest Med. 2003;26:252–8.PubMed Pei Y. Molecular genetics of autosomal dominant polycystic kidney disease. Clin Invest Med. 2003;26:252–8.PubMed
4.
go back to reference Fall PJ, Prisant LM. Polycystic kidney disease. J Clin Hypertens. 2005;7:617–9.CrossRef Fall PJ, Prisant LM. Polycystic kidney disease. J Clin Hypertens. 2005;7:617–9.CrossRef
5.
6.
go back to reference Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and micro-albuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1349–54.PubMed Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and micro-albuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1349–54.PubMed
7.
go back to reference Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205–12. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205–12.
8.
go back to reference Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol. 1991;11:653–60.PubMed Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol. 1991;11:653–60.PubMed
9.
go back to reference Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;5:2048–56.PubMed Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;5:2048–56.PubMed
10.
go back to reference Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology. 2006;11:124–30.PubMedCrossRef Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology. 2006;11:124–30.PubMedCrossRef
11.
go back to reference Chapman AB, Gabow PA. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1997;52(Suppl 61):S71–3. Chapman AB, Gabow PA. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1997;52(Suppl 61):S71–3.
12.
go back to reference Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, Cavdar C, Ecder SA, Tokgoz B, Duman N, Duzova A, Turkish Society of Nephrology Polycystic Kidney Disease Working Group. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience. Nephron Clin Pract. 2011;117(3):c270–5.PubMedCrossRef Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, Cavdar C, Ecder SA, Tokgoz B, Duman N, Duzova A, Turkish Society of Nephrology Polycystic Kidney Disease Working Group. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience. Nephron Clin Pract. 2011;117(3):c270–5.PubMedCrossRef
13.
go back to reference Taylor M, Johnson AM, Tison M, Fain P, Schrier R. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis. 2005;46:415–23.PubMedCrossRef Taylor M, Johnson AM, Tison M, Fain P, Schrier R. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis. 2005;46:415–23.PubMedCrossRef
14.
go back to reference Ecder T, Schrier RW. Hypertension in autosomal-dominant poly cystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol. 2001;12:194–200.PubMed Ecder T, Schrier RW. Hypertension in autosomal-dominant poly cystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol. 2001;12:194–200.PubMed
15.
go back to reference Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41:1311–9.PubMedCrossRef Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41:1311–9.PubMedCrossRef
16.
go back to reference Schrier RW, McFann K, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678–85.PubMedCrossRef Schrier RW, McFann K, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678–85.PubMedCrossRef
17.
go back to reference Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999;14:1113–6.PubMedCrossRef Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999;14:1113–6.PubMedCrossRef
18.
go back to reference Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5:2037–47.PubMed Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5:2037–47.PubMed
19.
go back to reference Schrier RW, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13:1733–9.PubMedCrossRef Schrier RW, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13:1733–9.PubMedCrossRef
20.
go back to reference Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21(2):98–103.PubMedCrossRef Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21(2):98–103.PubMedCrossRef
21.
go back to reference Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99(1):c18–23.PubMedCrossRef Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99(1):c18–23.PubMedCrossRef
22.
go back to reference Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67(1):265–71.PubMedCrossRef Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int. 2005;67(1):265–71.PubMedCrossRef
23.
go back to reference Bae K, Zhu F, Chapman A, Torres V, Grantham J, Guay-Woodford L, Baumgarten D, King BF, Wetzel LH, Kenney P, Brummer M, Bennett W, Klahr S, Meyers C, Zhang X, Thompson P, Miller J. Magnetic resonance imaging (MRI) evaluation of hepatic cysts in early autosomal dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Clin J Am Soc Nephrol. 2006;1:64–9.PubMedCrossRef Bae K, Zhu F, Chapman A, Torres V, Grantham J, Guay-Woodford L, Baumgarten D, King BF, Wetzel LH, Kenney P, Brummer M, Bennett W, Klahr S, Meyers C, Zhang X, Thompson P, Miller J. Magnetic resonance imaging (MRI) evaluation of hepatic cysts in early autosomal dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Clin J Am Soc Nephrol. 2006;1:64–9.PubMedCrossRef
24.
go back to reference Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P. Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;6(6):1634–42.PubMed Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P. Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;6(6):1634–42.PubMed
25.
go back to reference Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1992;20:140–3.PubMed Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1992;20:140–3.PubMed
26.
go back to reference Gibson P, Watson ML. Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant. 1998;13:2455–7.PubMedCrossRef Gibson P, Watson ML. Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant. 1998;13:2455–7.PubMedCrossRef
27.
go back to reference Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsed R, Johnson AM, Gabow P. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36:53–7.PubMedCrossRef Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsed R, Johnson AM, Gabow P. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36:53–7.PubMedCrossRef
28.
go back to reference Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal polycystic kidney disease. Am J Kidney Dis. 1993;22:513–9.PubMed Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal polycystic kidney disease. Am J Kidney Dis. 1993;22:513–9.PubMed
29.
go back to reference Orth SR, Stockman A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926–31.PubMedCrossRef Orth SR, Stockman A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926–31.PubMedCrossRef
30.
go back to reference Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int. 2011;80:516–23.PubMedCrossRef Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int. 2011;80:516–23.PubMedCrossRef
31.
go back to reference Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2012;16(4):622–8.PubMedCrossRef Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2012;16(4):622–8.PubMedCrossRef
Metadata
Title
Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience
Authors
Abdullah Ozkok
Timur Selcuk Akpinar
Fatih Tufan
Nilufer Alpay Kanitez
Mukremin Uysal
Metban Guzel
Yasar Caliskan
Sabahat Alisir
Halil Yazici
Tevfik Ecder
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0706-3

Other articles of this Issue 3/2013

Clinical and Experimental Nephrology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine